Anti-B7-H3 (enoblituzumab biosimilar) (MGA271)

Artikelnummer Größe Datenblatt Manual SDB Lieferzeit Menge Preis
ABE-12-9070-50 50 µg - -

3 - 11 Werktage*

534,00 €
ABE-12-9070-100 100 µg - -

3 - 11 Werktage*

638,00 €
 
Protein function: May participate in the regulation of T-cell-mediated immune response. May play... mehr
Produktinformationen "Anti-B7-H3 (enoblituzumab biosimilar) (MGA271)"
Protein function: May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. May be involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy. Both isoform 1 and isoform 2 appear to be redundant in their ability to modulate CD4 T-cell responses. Isoform 2 is shown to enhance the induction of cytotoxic T-cells and selectively stimulates interferon gamma production in the presence of T-cell receptor signaling. [The UniProt Consortium]
Schlagworte: Anti-B7H3, Anti-B7-H3, Anti-CD276, Anti-PSEC0249, Anti-4Ig-B7-H3, Anti-B7 homolog 3, Anti-CD276 antigen, Anti-Costimulatory molecule, Anti-B7-H3 Antibody (enoblituzumab biosimilar) (MGA271)
Hersteller: Abeomics
Hersteller-Nr: 12-9070

Eigenschaften

Anwendung: ELISA, FC
Antikörper-Typ: Monoclonal
Klon: MGA271
Konjugat: No
Wirt: Human
Spezies-Reaktivität: human
Format: Purified

Handhabung & Sicherheit

Lagerung: -20°C
Versand: -20°C (International: -20°C)
Achtung
Nur für Forschungszwecke und Laboruntersuchungen: Nicht für die Anwendung im oder am Menschen!
Hier kriegen Sie ein Zertifikat
oder , um Analysenzertifikate anzufordern.
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Anti-B7-H3 (enoblituzumab biosimilar) (MGA271)"
Bewertung schreiben
oder , um eine Produktbewertung abzugeben.
Zuletzt angesehen